STAT+: Brainstorm’s cell therapy for ALS fails study, but company sees signs of efficacy — and may push for approval
Brainstorm Cell Therapeutics reported disappointing results Tuesday from a late-stage clinical trial involving its experimental stem cell therapy for patients with amyotrophic lateral sclerosis, or Lou Gehrig’s disease.
In the Phase 3 study, three spinal injections of the bespoke treatment called NurOwn failed to slow the neurological decline of ALS patients compared to placebo injections. NurOwn performed as anticipated, but a better-than-expected placebo response caused the final analysis to miss statistical significance by a wide margin, Brainstorm said.
